Original Contribution
The American Journal of Gastroenterology (2005) 100, 295–298; doi:10.1111/j.1572-0241.2005.40793.x
Marked Elevation in Serum Transaminases: An Atypical Presentation of Choledocholithiasis
The authors dedicate this paper to the memory of Telfer Reynolds who passed away in June 2004.
Rahul A Nathwani MD1, S Ram Kumar MD1, Telfer B Reynolds MD1 and Neil Kaplowitz MD1
1Division of Gastrointestinal and Liver Disease, Department of Medicine, Los Angeles; Department of Surgery Keck School of Medicine of the University of Southern California, Los Angeles, California
Correspondence: Neil Kaplowitz, MD, Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine of the University of Southern California, 2011 Zonal Avenue, HMR#101, Los Angeles, CA 90033
Received 13 May 2004; Revised 0000; Accepted 5 August 2004.
Abstract
BACKGROUND:
Choledocholithiasis causes elevations in levels of alkaline phosphatase out of proportion to aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Isolated marked elevation in AST and ALT levels over 1,000 IU/L has been reported infrequently in patients with choledocholithiasis.
METHODS:
The charts of 18 patients who presented between 1971 and 2002 with documented choledocholithiasis and AST or ALT levels greater than 1,000 IU/L were retrospectively reviewed. An extensive work-up for coexisting disease processes to account for the abnormal AST and ALT levels was negative.
RESULTS:
Eighteen patients (16 women, 16 Hispanics, age 38 
3 yr) presented with symptoms of choledocholithiasis and marked transaminase elevation. Peak levels of AST and ALT were 1,062 129 and 1,119 90, respectively. Following successful management of gallstone disease, AST and ALT levels fell rapidly to 129 22 and 268 61, respectively, within 3–14 days. There was also a concomitant improvement in the levels of bilirubin and alkaline phosphatase.
CONCLUSIONS:
In the absence of other hepatobiliary or pancreatic disease, choledocholithiasis can result in elevations in AST and/or ALT greater than 1,000 IU/L. These levels fall markedly once the gallstone disease is appropriately managed.
